Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel
NASDAQ:XCUR

Exicure 8/8/2025 Earnings Report

Exicure logo
$3.37 +0.02 (+0.60%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$3.37 0.00 (0.00%)
As of 05/8/2026 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Exicure EPS Results

Actual EPS
-$0.41
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Exicure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Exicure Announcement Details

Quarter
Date
8/8/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Exicure's next earnings date is estimated for Wednesday, May 13, 2026, based on past reporting schedules.

Conference Call Resources

Exicure Earnings Headlines

Exicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination Therapies
April 22, 2026  |  quiverquant.comQ
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3279497/33289/en/exicure-announces-co-development-agreement-with-adbiotech-for-burixafor-gpc-100.html
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
May 9 at 1:00 AM  |  Profits Run (Ad)
Exicure Inc.
April 13, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/xcur/company-people
Exicure Strengthens Leadership With New COO and Director
April 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/exicure-strengthens-leadership-with-new-coo-and-director?utm_source=marketbeat.com&utm_medium=referral
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
April 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/02/3267814/33289/en/summary-notice-of-pendency-and-proposed-settlement-of-stockholder-derivative-actions.html
See More Exicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email.

About Exicure

Exicure (NASDAQ:XCUR) is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology. By leveraging the unique structural properties of SNA constructs, Exicure aims to improve cellular uptake, enhance pharmacokinetics and reduce off‐target effects compared with traditional nucleic acid therapies.

Founded on technology originating from Northwestern University, Exicure is headquartered in Skokie, Illinois, where it conducts its research, preclinical studies and early‐stage development activities. The company completed its initial public offering on the Nasdaq exchange under the ticker XCUR and maintains a focused R&D footprint in the Chicago area.

Exicure collaborates with academic institutions and biopharmaceutical partners to advance its SNA platform and expand its therapeutic reach. Guided by a management team with deep expertise in biotechnology innovation, the company is working to translate its nanotechnology into novel treatments for patients with high‐unmet medical needs around the world.

View Exicure Profile
Earnings Tools